Home » Stocks » Avalon GloboCare

Avalon GloboCare Corp. (AVCO)

Stock Price: $1.71 USD 0.01 (0.59%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 135.71M
Revenue (ttm) 1.51M
Net Income (ttm) -16.94M
Shares Out 79.36M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 8, 2020
Last Price $1.71
Previous Close $1.70
Change ($) 0.01
Change (%) 0.59%
Day's Open 1.68
Day's Range 1.68 - 1.74
Day's Volume 157,463
52-Week Range 0.50 - 2.65

More Stats

Market Cap 135.71M
Enterprise Value 138.77M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 79.36M
Float 25.06M
EPS (basic) -0.22
EPS (diluted) -0.22
FCF / Share -0.10
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 903,665
Short Ratio 4.90
Short % of Float 3.49%
Beta 0.71
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 90.06
PB Ratio 38.08
Revenue 1.51M
Operating Income -18.13M
Net Income -16.94M
Free Cash Flow -7.96M
Net Cash -3.06M
Net Cash / Share -0.04
Gross Margin 18.85%
Operating Margin -1,203.34%
Profit Margin -1,086.20%
FCF Margin -528.39%
ROA -93.04%
ROE -263.57%
ROIC -184.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue1.551.561.080.62-
Revenue Growth-1.02%44.99%74.8%--
Gross Profit0.340.390.250.54-
Operating Income-19.38-7.63-3.880.08-0.03
Net Income-18.07-7.77-3.460.06-0.03
Shares Outstanding75.1272.0065.0351.146.33
Earnings Per Share-0.24-0.11-0.05--
Operating Cash Flow-7.08-4.40-1.340.01-0.03
Capital Expenditures-0.39-0.50-7.06-0.70-
Free Cash Flow-7.47-4.90-8.40-0.69-0.03
Cash & Equivalents0.762.253.032.890.11
Total Debt3.191.001.50--
Net Cash / Debt-2.431.251.532.890.11
Assets10.4913.4012.673.710.11
Liabilities6.032.145.360.160.12
Book Value4.4712.127.893.55-0.01
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Avalon GloboCare Corp.
Country United States
Employees 7
CEO David K. Jin

Stock Information

Ticker Symbol AVCO
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Care Facilities
Unique Identifier NASDAQ: AVCO

Description

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. It also develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology. In addition, the company develops proprietary diagnostic and therapeutic products leveraging exosome technology; and provides development services for hospitals. The company has strategic partnerships with Weill Cornell Medical College to co-develop bio-production and standardization procedures for chimeric antigen receptor (CAR)-T Therapy; GensKey Medical Technology Co. Ltd. to co-develop and commercialize point-of-care, rapid detection antibody tests to identify whether a patient has been exposed to and has developed antibodies against SARS-CoV-2; GE Healthcare to enhance standardized automation and bio-production for cellular medicines; and HydroPeptide, LLC to co-develop and commercialize various clinical-grade, exosome-based cosmeceutical and orthopedic products, as well as a research agreement with Massachusetts Institute of Technology to develop CAR technology. It also has a strategic partnership with the University of Natural Resources and Life Sciences to develop an S-layer vaccine that can be administered by an intranasal or oral route against SARS-CoV-2, the novel coronavirus that causes COVID-19 disease. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.